Selected insights

Below are thought leadership pieces focused on structured products. These accounts provide insights from experts who have played a pivotal role in the field.

Industry has shown resilience, now it is at an inflection point

Over the last few years, the structured product industry has responded well to regulatory and transformational change.

29 Apr 2021 by David Wood - Luma Financial Technologies

Pharma in structured products (part 5) - option trading strategies and delta hedging

The next section of our analysis focuses on call butterfly, iron condor, bull call spread and bear put Spread option strategies and how adequately their profit potential has been realised in the case of Teva Pharmaceutical (Teva), BioMarin Pharmaceutical (BMRN), HCA Healthcare (HCA), Merck (MRK), and Fresenius Medical Care (FMS).

26 Mar 2021 by Filip Dyankov

Pharma in structured products (part 4) – technical analysis of pharmaceutical stocks

In this article we apply the Donchian Channel on a sample of 16 stocks – Amgen, Bayer, Biogen, BioNTech, CSPC Pharmaceutical Group, CVS Health, Exact Sciences, Fresenius, Gilead Sciences, Merck, Moderna, Pfizer, Sanofi, Teladoc Health, UnitedHealth, and Vertex Pharmaceutical), as well as the Chakin Moneyflow Index and Aroon Up/Down indicator on a set of five securities.

25 Mar 2021 by Filip Dyankov

Pharma in structured products (part 3) – performance and underlying analysis

In the third part of our analysis, we look at the markets that saw the best performance for pharma products during 2020 as well as modern portfolio theory (MPT) considerations and its deficiencies when applied to the structured product ecosystem.

24 Mar 2021 by Filip Dyankov

Pharma in structured products (part 2) - stagnating issuance in main pharma markets

Buoyant issuance in Malaysia, Belgium and France; reverse convertibles linked to pharma companies have been less affected than growth products, notably the leverage long with stop loss; US breakdown – CVS Health losing ground in sales, Merck records sustained growth.

23 Mar 2021 by Filip Dyankov

Pharma in structured products - issuance & sales

Underlying analysis of pharma-based structured products amid a challenging economic climate shows falling sales and issuance.

22 Mar 2021 by Filip Dyankov

Gamestop: a modern stock drama

Just when experienced traders and investors think they have seen everything, something unexpected always comes along.

16 Feb 2021 by Tim Mortimer - FVC

Understanding the Greeks: all pricing parameters

This article is the second part of a survey on the importance and role of Greeks in structured products and derivatives.

31 Jan 2021 by Tim Mortimer, FVC

Meet the ‘Greeks’: first order sensitivities

This article is the first of two pieces looking at the importance and role of ‘Greeks’ in structured products and derivatives.

27 Nov 2020 by Tim Mortimer

Interested in how structured products intelligence can power your business?

Request a demo

Who we are

Launched in 2003, SRP is the leading provider of intelligence for the global structured product market, trusted by investment banks, hedge funds, product issuers and distributors, exchanges and asset managers.

Today, we enable market players to find any product from over 40 million in our database and easily analyse the market. Our news service and global events cover the latest insights into the structured products market and recognises industry leading talent through our awards programmes.

Learn more

( History of structured productsPrev FAQs - structured productsNext )